ABSTRACT
INTRODUCTION
Threatened preterm labor is a common complaint in obstetric emergency units. Triaging women with threatened preterm labor is essential for planning further management, since the majority of them will eventually deliver at term. Cervical length (CL) measurement, with or without evaluation of cervicovaginal fetal fibronectin, is currently the main triage method 1 . CL alone has moderate accuracy in predicting preterm birth in symptomatic women; for example, the CL cut-off of 25 mm has approximately 70% sensitivity for predicting birth before 37 weeks' gestation, at a false-positive rate (FPR) of approximately 30% 2 .
Relaxin is a polypeptide that is structurally related to insulin and the insulin-like growth factors. In pregnancy, circulating relaxin is produced by the corpus luteum. The placenta and decidua also produce relaxin, but this fraction has an autocrine or paracrine action rather than entering the circulation 3, 4 . In addition to its other functions related to maternal adaptation in normal pregnancy [5] [6] [7] , relaxin has also been implicated in the process of labor, both term and preterm 8, 9 . However, the data regarding changes in relaxin levels in preterm labor are conflicting. A study published in 1986 reported that serum relaxin levels were significantly lower in women who delivered within 1 week compared with those who did not, and the lowest levels were noted in one woman with threatened preterm labor who eventually delivered preterm 10 . In contrast, subsequent studies reported increased serum relaxin levels in women delivering preterm [11] [12] [13] [14] . Previous studies in asymptomatic women have shown that there is no association between CL and serum relaxin changes 14, 15 , which statistically allows their combination as possible predictors of preterm birth. This study aimed to investigate whether maternal serum relaxin is associated with preterm birth in symptomatic women, either as a standalone test or in a combined model of serum relaxin and CL.
METHODS

Study design
This was a case-control study of women with a singleton pregnancy, presenting with symptoms of preterm labor between 24 + 0 and 26 + 6 weeks' gestation. The study was carried out at the Second Department of Obstetrics and Gynecology, Ippokrateio General Hospital, Thessaloniki, Greece, between December 2013 and December 2015. Women were enrolled prospectively in the study when they presented to the obstetric emergency department with symptoms of threatened preterm labor between 24 + 0 and 26 + 6 weeks' gestation. The outcomes of the participants were collected in August 2016. Women who eventually delivered preterm (before 37 weeks) were compared with those who delivered at term (controls). The study was approved by the Bioethics Committee of Aristotle University of Thessaloniki, Greece, and informed consent was obtained from all participants. The study is reported according to STROBE guidelines.
Participants
Of the initial population of women presenting with symptoms of preterm labor, we analyzed women with a singleton pregnancy, intact membranes and symptoms of threatened preterm labor between 24 + 0 and 26 + 6 confirmed gestational weeks. The upper gestational age limit of 26 + 6 weeks was chosen to increase homogeneity of our sample and to allow analysis of earlier cut-offs for prematurity. Women with preterm rupture of membranes, cervical cerclage, administration of progesterone vaginally, placenta previa, known Müllerian anomalies, history of cervical conization, pre-eclampsia or multiple pregnancy, and fetuses with intrauterine growth restriction or known structural anomalies were excluded. Cases of iatrogenic preterm birth were also excluded.
According to the protocol of our department, women with threatened preterm labor are offered inpatient investigation for at least 2 days, involving CL measurement, full blood count, C-reactive protein (CRP) measurement, liver function tests and glucose measurement. In women who consented to participate in the study, an additional blood sample was taken for the measurement of relaxin. Women who were admitted received tocolysis for 2 days and antenatal corticosteroids; maintenance tocolysis (nifedipine) was considered in the event of recurring threatened preterm labor.
Variables
Threatened preterm labor was defined as at least four regular uterine contractions per 20 min, reported by the patient or recorded on external tocography, accompanied by lower abdominal pain, with or without vaginal bloody or mucosanguineous discharge. Preterm birth was defined as spontaneous (non-iatrogenic) birth occurring before 37 + 0 weeks' gestation. Latency was defined as the time interval between presentation and birth. Recorded maternal parameters included age, parity, previous preterm birth, body mass index (BMI), smoking habit and chronic use of medication.
Data sources and measurement
A comprehensive medical history was obtained from all women at presentation. A speculum examination was performed in all women claiming to have vaginal discharge. Standard blood tests included full blood count, serum CRP, liver-function tests and urine analysis. A transabdominal ultrasound scan was performed in all women to ensure fetal wellbeing.
CL was measured transvaginally in all women, as described by The Fetal Medicine Foundation 16 , using an Aloka 3500 ultrasound machine (Aloka Ltd, Tokyo, Japan) with a 7-MHz 120
• intracavitary transducer.
Blood samples were collected immediately after the ultrasound scan. The samples for measurement of maternal serum relaxin concentration were placed in dry sterile tubes, cooled to room temperature, centrifuged (1.6 g for 15 min) and finally stored at -20
• C until the day of analysis. All analyses were performed using the same batch of test materials. Serum relaxin level was measured using an enzyme-linked immunosorbent assay by Quantikine ® Colorimetric Sandwich Elisa (R & D Systems, Inc., Minneapolis, MN, USA). According to this technique, microplates that have been pre-coated with a monoclonal antibody specific for relaxin-2 are used. Standards and samples are pipetted into the wells, and any relaxin-2 present is bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked polyclonal antibody specific for relaxin-2 is added to the wells. Following a further wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of relaxin-2 bound in the initial step. After color development stops, its intensity is measured. According to the manufacturer, the measuring range of the method is 7.8-500 pg/mL, the intra-assay coefficient of variation is < 10% and the linearity of the test has been confirmed for dilutions up to 1:16.
Bias
Obstetric management of the participating women was dictated by their clinical circumstances. The research samples were analyzed after completion of the study, and the results did not affect clinical management.
Statistical analysis
Descriptive statistics were used to summarize continuous (mean ± SD) or categorical (proportion (95% CI)) variables. Comparisons between the two groups (preterm and term birth) were performed using the t-test for continuous variables and the chi-square test for categorical variables. The non-parametric Mann-Whitney U-test was used for comparison of the number of previous births, because of its limited possible values.
In order to account for potential confounders, we tested whether maternal characteristics and serum markers at presentation could predict birth before 37 weeks and birth before 34 weeks using logistic regression analysis (backward, by likelihood ratios). Potential predictors included maternal age, previous birth, previous preterm birth, BMI, smoking status, gestational age at presentation, white blood cell (WBC) count, CRP and relaxin levels. The predicted probabilities of the resulting model were saved as a separate variable, and their predictive accuracy (i.e. the trade-offs between sensitivity and FPR for predicting preterm birth) was assessed using receiver-operating characteristics (ROC) curve analysis. ROC curve analysis was also used to assess separately the predictive accuracy of CL and serum relaxin.
RESULTS
During the study period, 819 women presented to the obstetric emergency unit of our department with a singleton pregnancy and threatened preterm labor, and 395 of them were admitted for ≥ 48 h. Of these, 302 women consented to participate in the study, of whom 133 were between 24 + 0 and 26 + 6 weeks' gestation at enrollment. After excluding 21 cases who developed preterm prelabor rupture of membranes (PPROM) on admission, 46 women delivered preterm (study group) and 66 women delivered at term (control group) (Figure 1) . Most of the preterm infants (44/46) were delivered before 34 weeks.
Descriptive data of the two groups are shown in Table 1 . The only differences in background characteristics between the two groups were higher BMI (P = 0.031) and smoking being marginally more common (P = 0.048) in women who delivered preterm than in the control group. WBC count and CRP levels did not differ between the two groups. Women who delivered preterm had significantly lower mean CL and significantly higher mean serum relaxin level than did those who delivered at term (Figure 2) .
The predictive accuracy of serum relaxin level for birth before 37 weeks (n = 46) is illustrated in Figure 3 . For a FPR of 10%, which corresponds to a value of 1010 pg/mL, serum relaxin alone had 63.0% sensitivity for the prediction of birth before 37 weeks (Table 2 ). Regression analysis showed that CL (odds ratio (OR), 0.748) and serum relaxin level (OR, 1.002) were the only significant independent predictors of birth before 37 weeks. The combined model could predict 70.0% of births before 37 weeks at a FPR of 10% ( Table 2) CI, 0.641-0.858)), although the confidence intervals overlapped (Figure 3) . Similarly, for the prediction of birth before 34 weeks (n = 44), regression analysis showed that CL (OR, 0.850) and serum relaxin (OR, 1.001) were the only significant independent predictors. The combined model could predict 71% of births before 34 weeks at a FPR of 10% ( Table 2 ). The AUC was 0.726 (95% CI, 0.614-0.838) for relaxin alone, 0.795 (95% CI, 0.711-0.879) for CL alone and 0.869 (95% CI, 0.802-0.937) for their combination (Figure 4) . Sensitivities of the two markers alone and in combination for the prediction of birth before 37 and before 34 weeks, at different FPRs, are shown in Table 2 . Data are presented as mean ± SD, n (%), median (range) or n/N. *Data refer to parous women. BMI, body mass index; CL, cervical length; CRP, C-reactive protein; GA, gestational age; WBC, white blood cell.
There was no correlation between serum relaxin level and CL, either in the preterm (P = 0.812) or the term (P = 0.541) group. CL < 15 mm was found in 13/46 women who delivered preterm (sensitivity, 28.3% (95% CI, 17.3-42.6%)) vs in none in the term group. In women with a CL > 15 mm, a relaxin level > 1010 pg/mL was found in 19/33 (57.6%) women who delivered preterm vs 10.6% of those who delivered at term.
DISCUSSION
Principal findings
In this case-control study, we found that serum relaxin level in second-trimester symptomatic women with intact membranes is significantly higher in cases delivering preterm. At a 10% FPR, the sensitivity point estimates of relaxin exceeded those of CL, although the CIs overlapped widely. Regression analysis of potential demographic and clinical predictors showed that CL and serum relaxin were the only significant independent predictors of preterm birth, and their combination had the highest AUC point estimates for preterm birth before 37 and before 34 weeks. Serum relaxin level > 1010 pg/mL had a sensitivity of 58% for the prediction of preterm birth in women with a CL > 15 mm, for a 10% FPR.
Strengths and limitations
The main strengths of the study are its prospective design, the use of a standard methodology for CL measurement and that all blood tests were performed in a single laboratory, all of which eliminate interobserver variation. The main limitation of the study is its case-control design, which was preferred over the methodologically superior prospective cohort design, for reasons of logistics, resources and cost. Owing to the case-control design of the study, it was not possible to calculate predictive values, since they are prevalence-dependent. Moreover, the small sample size prevented us from assessing robustly the predictive performance of CRP, which was positive (above 5 mg/dL) in only two cases, and from analyzing the predictive value of relaxin and CL for birth within 7 days from presentation, as eight of nine such cases were enrolled after 27 weeks ( Figure 1 ).
Interpretation
We found that, in symptomatic second-trimester women with a singleton pregnancy and intact membranes, relaxin alone had a sensitivity of 63% for the prediction of birth before 37 weeks, at a FPR of 10%. This compares favorably with the sensitivity of 59% at a 19% FPR for CL < 20 mm and sensitivity of 71% at a 30% FPR for CL < 25 mm reported in the literature 2 . In fact, ROC curve analysis shows that the sensitivity of relaxin may exceed that of CL at lower FPRs, for example 10% (as shown in Figure 3 ). The slope of the curve changes after that point, so that the performance of CL catches up with that of relaxin as FPRs increase and the CIs overlap. The predictive performance of relaxin in our study was similar to that of fetal fibronectin reported previously, i.e. 66.8% sensitivity for birth before 37 weeks at a FPR of 18% 17 . Serum relaxin levels in normal pregnancies increase until the 10 th to 12 th gestational week, reaching a range of 1000-1200 pg/mL, then gradually decrease from the 12 th until the 24 th week, and finally rise again a few days before the onset of labor 18, 19 . To the best of our knowledge, this is the first study measuring both serum relaxin levels and CL in women with threatened preterm labor. Previous studies have reported an association between increased serum relaxin levels and preterm birth in asymptomatic women 12, 14, 15 . Vogel et al. 13 reported that increased serum relaxin, defined as > 300 pg/mL, was positively associated with birth before 34 weeks and birth within 3 days from presentation in women with threatened preterm birth. In that study, the AUC of relaxin was 69% (95% CI, 57-79%) for the prediction of birth before 34 weeks, which is similar to the AUC value of 75% (95% CI, 64-86%) that we observed for the prediction of birth before 37 weeks. However, the Danish study 13 also included women with PPROM, did not measure CL, and the mean gestational age at presentation was 31 weeks (vs 25.5 weeks in our study). The earlier gestational age at presentation in our study may account for the mean serum relaxin levels (1853 and 613 pg/mL in preterm and term births, respectively) being much higher in our study than those (203-316 pg/mL) reported in the Danish study.
The highest point estimate for predictive accuracy for preterm birth in our study was achieved through a combination of CL and serum relaxin measurement (AUC, 89% (95% CI, 83-95%)). Given that relaxin upregulates matrix metalloproteinases (MMPs) in human cervical fibroblasts in vitro, it has been hypothesized that increased levels of relaxin are associated with preterm birth through cervical softening and ripening 4 . However, in agreement with previous studies 12, 14, 15 , we found that relaxin levels do not correlate with CL in either women who deliver preterm or those who deliver at term. Therefore, cervical shortening does not appear to be mediated by relaxin 14, 15 . In fact, the physiological link between increased serum relaxin and preterm birth has still not been entirely elucidated. In pregnancy, relaxin is produced by the placenta, membranes and decidua, and exerts both local and systemic effects 4 . Experimental data show that relaxin can augment the intrauterine inflammatory response 20 , affect myometrial contractility through cyclooxygenase-1 (COX-1) and COX-2 activation 21 , and upregulate MMPs 8 . Even so, serum levels of relaxin are not necessarily expected to reflect accurately the local concentration and effects of the hormone at the choriodecidual level. Since serum relaxin levels and CL are not associated, the combination of the two parameters is statistically plausible and they can be used complementarily. Indeed, we found that increased serum relaxin (> 1010 pg/mL) had a sensitivity of 58% for predicting preterm birth in women with a CL > 15 mm. In this context, the function of relaxin seems to be similar to that of cervicovaginal fibronectin, which is also not correlated with CL, and may improve the prediction of preterm birth in symptomatic women with a CL > 15 mm 22 .
Generalizability
This study provides evidence that serum relaxin can be used as a marker for the prediction of preterm birth in symptomatic women with a singleton pregnancy in the second trimester. Although similar results were reported previously for asymptomatic twin pregnancies 14 , caution should be exercised before extrapolating our findings to twin pregnancies with threatened preterm labor. Similarly, we should be cautious before extrapolating these results to advanced gestational stages, given the physiological variation of serum relaxin with gestational age 18, 19 .
Conclusions
High serum relaxin levels are associated with an increased risk for preterm birth in symptomatic women with a singleton pregnancy and intact membranes in the second trimester. Relaxin does not correlate with CL, and the two factors can be combined to improve the predictive accuracy for preterm birth.
